MBS-303(MBS-303) - CD20 x CD3_

mbs303 MBS 303 is a bispecific antibody targeting CD3CD20 being developed by Beijing Mabworks Biotech for the treatment of B cell non-Hodgkin lymphoma. The. MBS303, composed of a 2:1 bispecific antibody structure, binds to CD20 with two arms and CD3 molecule with one arm to increase affinity with tumor cells and decrease the off-target toxicity

mbs303, MBS303-B-AX-0RAA Vitrohm Resistor Hardware Dummy pin datasheet, inventory, & pricing..